Abstract Number WESS104 4th IAS, Sydney, July 2007 A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, Maraviroc Versus Efavirenz, both.
Transcript Abstract Number WESS104 4th IAS, Sydney, July 2007 A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, Maraviroc Versus Efavirenz, both.